Before You Commit to a Hard-to-Recruit Trial Timeline, Check These 17 Failure Points.

Hard-to-Recruit Studies Often Go Wrong Before Recruitment Even Starts

When enrollment falls behind plan, teams often respond with:

• more sites,
• more advertising,
• more recruitment vendors,
• more coordinators,
• more sponsor meetings,
• or more budget.

But those actions only help if the real problem is capacity.

Many recruitment problems start earlier:

• protocol assumptions are too optimistic,
• inclusion/exclusion criteria are difficult to operationalize,
• patient data is incomplete,
• referral pathways are unclear,
• sites cannot recontact patients efficiently,
• consent and source-data workflows are disconnected,
• coordinators spend too much time on low-probability candidates,
• participants face travel or reimbursement friction,
• or payments are delayed after milestones are completed.

A study can have good technology and still have a broken participant journey.

The purpose of this checklist is to find those risks before they become rescue problems.

5. The 17-Point Hard-to-Recruit Study Launch Checklist

SECTION A — Protocol & Patient Match Risk

1. Can the eligibility criteria be operationalized consistently?

Ask:

• Are the inclusion and exclusion criteria clearly interpretable?
• Will two coordinators screen the same candidate the same way?
• Are criteria buried in free text, medical notes, historical labs, or longitudinal records?
• Are there criteria that will require repeated manual clarification?

2. Is the eligible population actually large enough in the target geographies?

Ask:

• Is prevalence being confused with recruitable prevalence?
• Are patients concentrated around specific centers of excellence?
• Are geography and travel requirements realistic?
• Is the target population already heavily competed for?

3. Can sites identify likely candidates before spending coordinator time?

Ask:

• Can sites run structured searches?
• Can relevant EHR data be queried?
• Are important eligibility signals available electronically?
• Does candidate identification still depend primarily on manual chart review?

4. Is enough data available before formal screening?

Ask:

• Can prior labs be accessed?
• Can medication history be verified?
• Are historical diagnoses available?
• Are prior imaging or biomarker results accessible?
• Does the site need to repeat tests simply because evidence cannot be retrieved?

SECTION B — Referral & Recontact Risk

5. Is ownership of patient outreach unambiguous?

Ask:

• Who identifies the candidate?
• Who is allowed to contact them?
• Is outreach performed by the site, provider, patient recruitment vendor, or another party?
• What happens when a candidate originates outside the principal investigator's direct patient population?

6. Can provider and center-of-excellence referrals move quickly?

Ask:

• Are referral pathways documented?
• Can specialty clinics refer into the study without excessive administrative burden?
• Is there a feedback loop to the referring clinician?
• Can the research team tell whether a referral has progressed?

7. Is there a compliant route from deidentified discovery to patient recontact?

Ask:

• Can the organization identify promising cohorts without exposing unnecessary identifiers?
• Is there a clear process for provider-mediated recontact?
• Are permissions and responsibilities documented?
• Does the recontact process change between sites or jurisdictions?

SECTION C — Site Conversion Risk

8. Are sites being measured on conversion, not only patient volume?

Track:

• candidates identified,
• contacted,
• pre-screened,
• screen-failed,
• consented,
• randomized.

A site with fewer candidates but strong conversion may outperform a high-volume site with weak conversion.

9. Are screen failures categorized by root cause?

Typical categories might include:

• true clinical ineligibility,
• missing medical evidence,
• protocol misunderstanding,
• timing/window failure,
• competing medication,
• participant refusal,
• travel burden,
• consent friction,
• operational delay.

10. Does the coordinator know what is missing before screening?

Ask:

• Can missing records be identified ahead of the visit?
• Can the coordinator see required eligibility evidence?
• Can the system flag missing labs or documents?
• Are patients arriving before the team knows whether key evidence exists?

SECTION D — Consent & Data Access Risk

11. Does consent move with the participant journey?

Ask:

• Is consent status visible to the people who need it?
• Can teams tell exactly what the participant agreed to?
• Are consent scope and data-access permissions aligned?
• Is re-consent easy when circumstances change?

12. Can the team prove who accessed what data and under which permission?

Ask:

• Is access logged?
• Can permissions expire?
• Can access be revoked?
• Can the organization identify what authorization existed at the moment of access?

13. Can the study obtain the required external clinical data without creating site burden?

Ask:

• Are EHR connections available?
• Does the patient need to manually retrieve records?
• Are staff downloading and uploading PDFs?
• Are records being rekeyed into another system?

SECTION E — Participant Burden & Retention Risk

14. Has the study quantified the participant's real burden?

Look beyond visits.

Consider:

• travel,
• childcare,
• missed work,
• parking,
• overnight stays,
• repeated assessments,
• device use,
• digital tasks,
• data-sharing requests,
• reimbursement delays.

15. Is reimbursement friction removed before the patient incurs the cost?

Ask:

• Does the patient need to pay first?
• How long until reimbursement?
• Are receipts required?
• Who handles exceptions?
• Can travel support be arranged in advance? Red flag: the trial technically reimburses participants, but still requires them to finance participation.

SECTION F — Payment & Milestone Risk

16. Can a completed participant milestone trigger payment without manual reconciliation?

Ask:

• What system confirms the milestone?
• Who verifies it?
• Does someone manually transfer the information?
• Does finance need another approval?
• Can the participant see payment status?

17. Can the CRO see the entire participant journey from match to paid milestone?

The ideal journey should be measurable:

Candidate identified → Contacted → Pre-screened → Consent obtained → Eligibility evidence confirmed → Screened → Randomized → Milestone completed → Participant paid

Ask:

• Is each transition measurable?
• Is the owner clear?
• Is elapsed time visible?
• Is failure reason captured?

6. Quick Scoring Method

Score Each Item

Green — Controlled

The workflow is clear, measurable, and largely automated or reliably governed.

Amber — Fragile

The process works but depends on manual coordination, individual knowledge, or inconsistent handoffs.

Red — High Risk

The workflow is unclear, highly manual, difficult to measure, or regularly causes delay.

Interpret the Result

0–3 Red Items

The recruitment model appears operationally sound.

Focus on optimization and monitoring.

4–7 Red Items

The study has meaningful participant-journey leakage.

Prioritize the highest-impact handoffs before enrollment volume increases.

8+ Red Items

The recruitment plan may be carrying significant operational risk.

Adding sites, vendors, or recruitment spend before fixing the underlying handoffs may increase cost without solving the root constraint.

7. Internal Review Worksheet Use this simple table internally.

Found the Risk. Now Quantify What It Costs.

This checklist tells you where participant-journey leakage may exist.

The next question is:

What is it adding to your cost per randomized patient?

Use the MinervaLedger Cost-per-Randomized-Patient Leakage Calculator to estimate the financial impact of:

• excess screen failures,
• coordinator workload,
• enrollment delays,
• manual consent and data handoffs,
• participant payment delays,
• and site burden.

CTA Button

CTA Supporting Copy

Use one active or upcoming study.

The calculator will help you identify which leakage category is worth fixing first.

This can be turned into a 2–3 page PDF.

Hard-to-Recruit Study Launch Checklist 17 Failure Points to Fix Before First Patient In

Before committing to a recruitment timeline for a difficult oncology, rare disease, CNS or hybrid study, review these 17 operating risks.

Protocol & Match

• Eligibility criteria can be operationalized consistently
• Recruitable population has been validated by geography
• Sites can identify likely candidates efficiently
• Required evidence is available before screening

Referral & Recontact

• Patient outreach ownership is clear
• Provider/COE referral pathways are operational
• Deidentified cohort discovery can transition into compliant recontact

Site Conversion

• Site conversion is measured across the whole funnel
• Screen failures are categorized by cause
• Missing eligibility evidence is identified before screening

Consent & Data

• Consent state is operationally visible
• Data access is permission-aware and auditable
• External clinical data can be retrieved without excessive site burden

Participant Burden

• Participant burden has been quantified
• Reimbursement does not require avoidable patient financing

Payment & Milestones

• Completed milestones can trigger payment efficiently
• The journey from candidate match to paid milestone is measurable end to end

Score the Study For each item:

Green = controlled Amber = fragile Red = high risk

Study Name:

Therapeutic Area:

Planned First Patient In:

Number of Red Items:

Top 3 risks:

1. 2. 3.

Action before FPI:

1. 2. 3.

Know Where the Leakage Is?

Now calculate what it may be costing you.

The Cost-per-Randomized-Patient Leakage Calculator estimates the financial impact of:

• screen failures,
• coordinator time,
• enrollment delay,
• manual handoffs,
• participant payment friction,
• and site burden.